$241 B

PFE Mkt cap, 13-Feb-2019

$13.3 B

Pfizer Revenue Q3, 2018
Pfizer Gross profit (Q3, 2018)10.6 B
Pfizer Gross profit margin (Q3, 2018), %79.7%
Pfizer Net income (Q3, 2018)4.1 B
Pfizer EBIT (Q3, 2018)4.1 B
Pfizer Cash, 30-Sep-20183.6 B
Pfizer EV278.5 B

Pfizer Revenue

Pfizer revenue was $52.55 b in FY, 2017 which is a 0.5% year over year decrease from the previous period.

Embed Graph

Pfizer Revenue Breakdown

Embed Graph

Pfizer revenue breakdown by business segment: 59.8% from Innovative Health and 40.2% from Essential Health

Pfizer revenue breakdown by geographic segment: 21.7% from Emerging Markets, 12.6% from Developed Rest of World, 16.2% from Developed Europe and 49.5% from United States

Pfizer Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

48.9b52.8b52.5b

Revenue growth, %

(2%)8%(1%)

Cost of goods sold

9.6b12.3b11.2b

Gross profit

39.2b40.5b41.3b

Gross profit Margin, %

80%77%79%

Sales and marketing expense

14.8b14.8b14.8b

R&D expense

7.7b7.9b7.7b

Operating expense total

22.5b22.7b22.4b

Depreciation and amortization

3.7b4.1b4.8b

EBIT

7.0b7.2b21.4b

EBIT margin, %

14%14%41%

Pre tax profit

9.0b8.4b12.3b

Income tax expense

2.0b1.1b(9.0b)

Net Income

7.0b7.2b21.3b

Pfizer Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

3.6b2.6b1.3b

Inventories

7.5b6.8b7.6b

Current Assets

43.8b38.9b41.1b

PP&E

13.8b13.3b13.9b

Goodwill

48.2b54.4b56.0b

Total Assets

167.4b171.6b171.8b

Accounts Payable

3.6b4.5b4.7b

Dividends Payable

1.9b1.9b2.0b

Short-term debt

10.2b10.7b10.0b

Current Liabilities

29.4b31.1b30.4b

Long-term debt

28.7b31.4b33.5b

Total Debt

38.9b42.1b43.5b

Total Liabilities

102.4b111.8b100.1b

Common Stock

459.0m461.0m464.0m

Preferred Stock

26.0m24.0m21.0m

Additional Paid-in Capital

81.0b82.7b84.3b

Retained Earnings

72.0b71.8b85.3b

Total Equity

65.0b59.8b71.7b

Debt to Equity Ratio

0.6 x0.7 x0.6 x

Debt to Assets Ratio

0.2 x0.2 x0.3 x

Financial Leverage

2.6 x2.9 x2.4 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

2.6b3.4b2.1b4.1b2.6b2.8b2.3b2.7b3.6b

Inventories

7.6b7.6b7.5b7.4b7.6b7.9b8.1b8.1b8.2b

Current Assets

41.3b43.8b38.5b35.9b36.4b40.3b34.8b37.3b41.6b

PP&E

13.6b13.6b13.3b13.2b13.4b13.5b14.0b13.9b14.0b

Goodwill

48.6b50.6b56.3b54.7b55.0b56.1b56.4b55.8b55.6b

Total Assets

162.9b170.7b178.4b168.8b168.6b172.2b164.6b165.0b167.8b

Accounts Payable

3.1b3.3b3.5b3.4b3.4b3.5b3.9b4.2b4.3b

Dividends Payable

1.8b1.8b1.9b1.9b2.0b2.0b

Short-term debt

11.5b13.7b13.6b768.0m9.5b9.4b9.0b11.6b7.4b

Current Liabilities

28.7b32.1b34.8b24.9b27.2b28.2b27.4b32.2b29.0b

Long-term debt

27.8b30.5b30.4b36.3b34.2b34.5b31.8b28.9b33.7b

Total Debt

39.4b44.2b44.1b37.1b43.7b44.0b40.8b40.5b41.0b

Total Liabilities

99.6b107.6b114.8b110.0b109.9b111.0b94.1b94.9b96.2b

Common Stock

460.0m461.0m461.0m463.0m463.0m463.0m465.0m465.0m466.0m

Preferred Stock

26.0m25.0m25.0m23.0m23.0m22.0m21.0m20.0m20.0m

Additional Paid-in Capital

81.4b82.1b82.5b83.1b83.4b83.8b84.6b84.9b85.8b

Retained Earnings

75.0b73.4b72.8b74.8b74.1b75.0b90.0b89.9b92.0b

Total Equity

63.3b63.1b63.6b58.7b58.7b61.1b70.5b70.1b71.7b

Debt to Equity Ratio

0.6 x0.7 x0.7 x0.6 x0.7 x0.7 x0.6 x0.6 x0.6 x

Debt to Assets Ratio

0.2 x0.3 x0.2 x0.2 x0.3 x0.3 x0.2 x0.2 x0.2 x

Financial Leverage

2.6 x2.7 x2.8 x2.9 x2.9 x2.8 x2.3 x2.4 x2.3 x

Pfizer Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

7.0b7.2b21.4b

Depreciation and Amortization

5.2b5.8b6.3b

Accounts Receivable

21.0m(134.0m)259.0m

Inventories

(199.0m)365.0m(357.0m)

Accounts Payable

254.0m871.0m46.0m

Cash From Operating Activities

14.7b15.9b16.5b

Purchases of PP&E

(1.4b)(1.8b)(2.0b)

Cash From Investing Activities

(3.0b)(7.8b)(4.7b)

Short-term Borrowings

(4.0b)(5.1b)(10.0b)

Long-term Borrowings

(3.0b)(7.7b)(6.2b)

Dividends Paid

(6.9b)(7.3b)(7.7b)

Cash From Financing Activities

(10.4b)(8.9b)(13.0b)

Net Change in Cash

298.0m(1.0b)(1.3b)

Interest Paid

1.3b1.5b1.5b

Income Taxes Paid

2.4b2.5b2.5b

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

3.0b5.1b6.5b3.1b6.2b9.1b3.6b7.4b11.6b

Depreciation and Amortization

1.4b2.8b4.2b1.6b3.1b4.7b1.6b3.1b4.7b

Cash From Operating Activities

1.8b5.4b1.0b1.6b4.8b9.7b2.0b5.8b11.1b

Purchases of PP&E

(301.0m)(702.0m)(1.1b)(358.0m)(806.0m)(1.3b)(386.0m)(810.0m)(1.4b)

Cash From Investing Activities

4.4b(323.0m)(4.7b)4.8b3.0b19.0m9.7b8.2b5.3b

Short-term Borrowings

(1.3b)(2.3b)(3.3b)(2.5b)(5.1b)(7.7b)(83.0m)(2.9b)(4.2b)

Long-term Borrowings

(1.5b)(4.3b)(4.3b)(1.3b)(4.5b)(4.5b)(355.0m)(3.1b)(3.1b)

Dividends Paid

(1.9b)(3.7b)(5.5b)(1.9b)(3.9b)(5.7b)(2.0b)(4.0b)(6.0b)

Cash From Financing Activities

(7.1b)(5.3b)(6.9b)(4.9b)(7.9b)(9.6b)(10.7b)(12.6b)(14.0b)

Net Change in Cash

(1.1b)(230.0m)(1.5b)1.5b(5.0m)193.0m985.0m1.4b2.2b

Interest Paid

409.0m903.0m1.2b216.0m881.0m1.1b259.0m724.0m968.0m

Income Taxes Paid

518.0m1.1b1.4b195.0m1.1b1.4b257.0m1.2b1.7b

Pfizer Ratios

USDY, 2018

EV/EBIT

67.8 x

EV/CFO

25.1 x

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.3 x
Report incorrect company information

Pfizer Operating Metrics

Pfizer's Properties was reported to be 501 in FY, 2017.
FY, 2014FY, 2015FY, 2016FY, 2017

Active Clinical Studies

448 338

Phase III Trials Products

22 30 34 29

Discovery Projects

91 90 96 87

Countries

125 125

Manufacturing Sites

55 64 63 58

Properties

513 595 567 501

Total Units Delivered

74 b

Vaccines Delivered

135 m
Report incorrect company information

Pfizer Employee Rating

4.03219 votes
Culture & Values
3.8
Work/Life Balance
3.8
Senior Management
3.5
Salary & Benefits
3.9
Career Opportunities
3.6
Source